Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: A new genetically tractable model for human cancer associated fibroblasts

Cancer Biology and Therapy

Volumn 11, Issue 4, 2011, Pages 383-394

  Trimmer, Casey ^a,b   Sotgia, Federica ^a,b,d   Whitaker Menezes, Diana ^a,b   Balliet, Renee M ^a,b   Eaton, Gregory ^a,b   Martinez Outschoorn, Ubaldo E ^a,b,c   Pavlides, Stephanos ^a,b   Howell, Anthony ^d   Iozzo, Renato V ^b   Pestell, Richard G ^a,b,c   Scherer, Philipp E ^e   Capozza, Franco ^a,b   Lisanti, Michael P ^a,b,c,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Angiogenesis; Cancer associated fibroblast; Caveolin 1; Collagen 6 (COL6A1, COL6A2); Mitochondria; Myofibroblast differentiation; Oxidative stress; Superoxide disumutase (SOD2); Triple negative breast cancer; Tumor stroma

Indexed keywords

CAVEOLIN 1; COPPER ZINC SUPEROXIDE DISMUTASE; ESTROGEN RECEPTOR; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL ENZYME; RECOMBINANT PROTEIN; SHORT HAIRPIN RNA; TAMOXIFEN; TUMOR SUPPRESSOR PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER MODEL; CELL DIFFERENTIATION; CELL HYPOXIA; CELL IMMORTALIZATION; CONTROLLED STUDY; CYTOPLASM; FIBROBLAST; GENETIC MODEL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MOUSE; MYOFIBROBLAST; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PARACRINE SIGNALING; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; RNA INTERFERENCE; STROMA CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CAVEOLIN 1; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, NUDE; MITOCHONDRIA; MODELS, BIOLOGICAL; NEOPLASMS; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PROTEOMICS; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; SUPEROXIDE DISMUTASE; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79951833645     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.4.14101     Document Type: Article

References (61)

1. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001; 1:46-54. (Pubitemid 33741880)
2. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW. The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 2002; 70:537-46. (Pubitemid 36194318)
3. Ronnov-Jessen L, Bissell MJ. Breast cancer by proxy: can the microenvironment be both the cause and consequence? Trends Mol Med 2009; 15:5-13.
4. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121:335-48. (Pubitemid 40692295)
5. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006; 5:1597-601. (Pubitemid 44285243)
6. Toullec A, Gerald D, Despouy G, Bourachot B, Cardon M, Lefort S, et al. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol Med 2010; 2:211-30.
7. Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, Allen KG, et al. Human Breast Cancer-Associated Fibroblasts (CAFs) Show Caveolin-1 Downregulation and RB Tumor Suppressor Functional Inactivation: Implications for the Response to Hormonal Therapy. Cancer Biol Ther 2008; 7:1212-25.
8. Witkiewicz AK, Casimiro MC, Dasgupta A, Mercier I, Wang C, Bonuccelli G, et al. Towards a new "stromal-based" classification system for human breast cancer prognosis and therapy. Cell Cycle 2009; 8:1654-8.
9. Witkiewicz AK, Dasgupta A, Nguyen KH, Liu C, Kovatich AJ, Schwartz GF, et al. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther 2009; 8:1167-75.
10. Witkiewicz AK, Dasgupta A, Sammons S, Er O, Potoczek MB, Guiles F, et al. Loss of Stromal Caveolin-1 Expression Predicts Poor Clinical Outcome in Triple Negative and Basal-like Breast Cancers. Cancer Biol Ther 2010; 10:135-43.
11. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, et al. An Absence of Stromal Caveolin-1 Expression Predicts Early Tumor Recurrence and Poor Clinical Outcome in Human Breast Cancers. Am J Pathol 2009; 174:2023-34.
12. Sloan EK, Ciocca D, Pouliot N, Natoli A, Restall C, Henderson M, et al. Stromal Cell Expression of Caveolin-1 Predicts Outcome in Breast Cancer. Am J Pathol 2009; 174:2035-43.
13. Lisanti MP, Martinez-Outschoorn UE, Chiavarina B, Pavlides S, Whitaker-Menezes D, Tsirigos A, et al. Understanding the "lethal" drivers of tumor-stroma co-evolution: Emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor microenvironment. Cancer Biol Ther 2010; 10:537-42.
14. Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, Lisanti MP. An Absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial akt activation. Cell Cycle 2009; 8:2420-4.
15. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 2010; 9:3256-76.
16. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman JN, Chiavarina B, et al. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and dcis therapy with autophagy inhibitors. Cell Cycle 2010; 9:2423-33.
17. Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, hif1 induction and nfeκb activation in the tumor stromal microenvironment. Cell Cycle 2010; 9:3515-33.
18. Pavlides S, Tsirigos A, Migneco G, Whitaker-Menezes D, Chiavarina B, Flomenberg N, et al. The autophagic tumor stroma model of cancer: role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle 2010; 9:3485-505.
19. Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, et al. Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the "reverse warburg effect": a transcriptional informatics analysis with validation. Cell Cycle 2010; 9:2201-19.
20. Chiavarina B, Whitaker-Menezes D, Migneco G, Martinez-Outschoorn UE, Pavlides S, Howell A, et al. HIF1alpha functions as a tumor promoter in cancer associated fibroblasts and as a tumor suppressor in breast cancer cells: autophagy drives compartment-specific oncogenesis. Cell Cycle 2010; 9:3534-51.
21. Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides S, Chiavarina B, Bonuccelli G, Casey T, et al. The autophagic tumor stroma model of cancer or "battery-operated tumor growth": a simple solution to the autophagy paradox. Cell Cycle 2010; 9:4297-306.
22. Witkiewicz AK, Freydin B, Chervoneva I, Potoczek MB, Rizzo W, Rui R, et al. Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer Biol Ther 2010; 10:391-6.
23. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457:910-4.
24. Persoon-Rothert M, Egas-Kenniphaas JM, van der Valk-Kokshoorn EJ, Buys JP, van der Laarse A. Oxidative stress-induced perturbations of calcium homeostasis and cell death in cultured myocytes: role of extracellular calcium. Mol Cell Biochem 1994; 136:1-9. (Pubitemid 24299697)
25. Mattson MP. Oxidative stress, perturbed calcium homeostasis and immune dysfunction in Alzheimer's disease. J Neurovirol 2002; 8:539-50. (Pubitemid 36104719)
26. Kawamata H, Manfredi G. Mitochondrial dysfunction and intracellular calcium dysregulation in ALS. Mech Ageing Dev 2010; 131:517-26.
27. Contreras L, Drago I, Zampese E, Pozzan T. Mitochondria: The calcium connection. Biochim Biophys Acta 2010; 1797:607-18.
28. Gellerich FN, Gizatullina Z, Trumbeckaite S, Nguyen HP, Pallas T, Arandarcikaite O, et al. The regulation of OXPHOS by extramitochondrial calcium. Biochim Biophys Acta 2010; 1797:1018-27.
29. Masamune A, Watanabe T, Kikuta K, Satoh K, Shimosegawa T. NADPH oxidase plays a crucial role in the activation of pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2008; 294:99-108.
30. Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol 2002; 36:200-9. (Pubitemid 34146426)
31. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, et al. NAD(P)H oxidase 4 mediates transforming growth factorbeta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005; 97:900-7. (Pubitemid 41552675)
32. Gailit J, Marchese MJ, Kew RR, Gruber BL. The differentiation and function of myofibroblasts is regulated by mast cell mediators. J Invest Dermatol 2001; 117:1113-9. (Pubitemid 34205906)
33. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009; 15:1077-81.
34. Bondi CD, Manickam N, Lee DY, Block K, Gorin Y, Abboud HE, et al. NAD(P)H oxidase mediates TGFbeta1-induced activation of kidney myofibroblasts. J Am Soc Nephrol 2010; 21:93-102.
35. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, et al. The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009; 8:3984-4001.
36. Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, et al. The reverse warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle 2010; 9:1960-71.
37. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001; 276:38121-38.
38. Garcia-Cardena G, Martasek P, Siler-Masters BS, Skidd PM, Couet JC, Li S, et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin: Functional Significance of the NOS caveolin binding domain in vivo. J Biol Chem (Communication) 1997; 272:25437-40. (Pubitemid 27438846)
39. Migneco G, Whitaker-Menezes D, Chiavarina B, Castello-Cros R, Pavlides S, Pestell RG, et al. Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: Evidence for stromal-epithelial metabolic coupling. Cell Cycle 2010; 9:2412-22.
40. Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, et al. Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer's disease and "Neuron-Glia Metabolic Coupling". Aging (Albany NY) 2010; 2:185-99.
41. Bravard A, Sabatier L, Hoffschir F, Ricoul M, Luccioni C, Dutrillaux B. SOD2: a new type of tumor-suppressor gene? Int J Cancer 1992; 51:476-80.
42. Behrend L, Mohr A, Dick T, Zwacka RM. Manganese superoxide dismutase induces p53-dependent senescence in colorectal cancer cells. Mol Cell Biol 2005; 25:7758-69. (Pubitemid 41170136)
43. St Clair D, Zhao Y, Chaiswing L, Oberley T. Modulation of skin tumorigenesis by SOD. Biomed Pharmacother 2005; 59:209-14. (Pubitemid 40603335)
44. Oberley LW. Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed Pharmacother 2005; 59:143-8. (Pubitemid 40603325)
45. Venkataraman S, Jiang X, Weydert C, Zhang Y, Zhang HJ, Goswami PC, et al. Manganese superoxide dismutase overexpression inhibits the growth of androgen-independent prostate cancer cells. Oncogene 2005; 24:77-89. (Pubitemid 40143867)
46. Tsanou E, Ioachim E, Briasoulis E, Damala K, Charchanti A, Karavasilis V, et al. Immunohistochemical expression of superoxide dismutase (MnSOD) antioxidant enzyme in invasive breast carcinoma. Histol Histopathol 2004; 19:807-13. (Pubitemid 38855063)
47. Pani G, Colavitti R, Bedogni B, Fusco S, Ferraro D, Borrello S, et al. Mitochondrial superoxide dismutase: a promising target for new anticancer therapies. Curr Med Chem 2004; 11:1299-308. (Pubitemid 38585068)
48. Duan H, Zhang HJ, Yang JQ, Oberley LW, Futscher BW, Domann FE. MnSOD upregulates maspin tumor suppressor gene expression in human breast and prostate cancer cells. Antioxid Redox Signal 2003; 5:677-88. (Pubitemid 37315157)
49. Oberley LW. Anticancer therapy by overexpression of superoxide dismutase. Antioxid Redox Signal 2001; 3:461-72. (Pubitemid 32646036)
50. Zhong W, Oberley LW, Oberley TD, St. Clair DK. Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase. Oncogene 1997; 14:481-90. (Pubitemid 27087111)
51. Yan T, Oberley LW, Zhong W, St. Clair DK. Manganese-containing superoxide dismutase overexpression causes phenotypic reversion in SV40-transformed human lung fibroblasts. Cancer Res 1996; 56:2864-71. (Pubitemid 26175749)
52. Li JJ, Oberley LW, St. Clair DK, Ridnour LA, Oberley TD. Phenotypic changes induced in human breast cancer cells by overexpression of manganese-containing superoxide dismutase. Oncogene 1995; 10:1989-2000.
53. Borrello S, De Leo ME, Galeotti T. Defective gene expression of MnSOD in cancer cells. Mol Aspects Med 1993; 14:253-8.
54. Khan T, Muise ES, Iyengar P, Wang ZV, Chandalia M, Abate N, et al. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol 2009; 29:1575-91.
55. Pasarica M, Gowronska-Kozak B, Burk D, Remedios I, Hymel D, Gimble J, et al. Adipose tissue collagen VI in obesity. J Clin Endocrinol Metab 2009; 94:5155-62.
56. Halberg N, Khan T, Trujillo ME, Wernstedt-Asterholm I, Attie AD, Sherwani S, et al. Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol 2009; 29:4467-83.
57. Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA, et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest 2005; 115:1163-76. (Pubitemid 40629035)
58. Iyengar P, Combs TP, Shah SJ, Gouon-Evans V, Pollard JW, Albanese C, et al. Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene 2003; 22:6408-23. (Pubitemid 37281689)
59. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, et al. Ketones and lactate "fuel" tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 2010; 9:3506-14.
60. Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 2005; 382:669-78. (Pubitemid 40890994)
61. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14:518-27. (Pubitemid 351655218)